Physician profile
Benjamin Warren
NPI 1912402512
$4,166.87
in general payments reported to CMS, 2019-2025
17 companies · $871 in 2025
The $871 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.61 · 2023: $154 · 2024: $3,115 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,389 · Travel and Lodging: $1,672 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,388.77 |
| Travel and Lodging | $1,671.50 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,749.64 | 2021-2024 | Axios, Exalt Model D, Apollo Esg Nxt System |
| Genzyme Corporation | $278.84 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $234.90 | 2023-2025 | Entyvio, Gattex |
| Abbvie INC. | $192.90 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $163.71 | 2024-2025 | Dupixent |
| Janssen Biotech, INC. | $161.14 | 2024-2025 | Tremfya, Stelara |
| Conmed Corporation | $95.79 | 2025 | Conmed Generators |
| Ovesco Endoscopy USA, INC. | $74.75 | 2025 | |
| Pfizer INC. | $35.32 | 2025 | |
| Alcresta Therapeutics, INC. | $33.20 | 2024 | Relizorb |
| Phathom Pharmaceuticals, INC. | $30.14 | 2024 | Voquezna |
| Lilly USA, LLC | $30.01 | 2025 | Omvoh |
| Novo Nordisk INC | $20.81 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $20.25 | 2024 | |
| Ardelyx, INC. | $17.45 | 2025 | Ibsrela |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $14.31 | 2025 | Zenpep |
| Celltrion USA INC. | $13.71 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.